 |
|
|
| |
BMS-986036, a PEGylated Fibroblast Growth Factor 21 Analogue, Reduces Fibrosis and
PRO-C3 in a Mouse Model of Non-Alcoholic Steatohepatitis
|
| |
| |
EASL: An Integrated Safety Analysis of Phase 2 Studies of BMS-986036, a PEGylated Fibroblast Growth Factor 21 Analogue for the Treatment of Non-Alcoholic Steatohepatitis - (04/25/18)
EASL: Safety, Tolerability, and Pharmacokinetics of BMS-986263/ND-L02-s0201, A Novel Targeted Lipid Nanoparticle Delivering HSP47 siRNA, in Healthy Participants: A Randomised, Placebo-Controlled, Double-Blind, Phase 1 Study - (04/24/18)
Reported by Jules Levin
EASL 2018 April 11-15 Paris France
Yi Luo, John Krupinski, Sheng Gao, Edgar Charles, Rose Christian
Bristol-Myers Squibb, Princeton, New Jersey, USA
|
| |
|
|
|
|
|
